Model: Anti-tumor efficacy

Anti-tumor efficacy models evaluate the therapeutic efficacy of a specific therapy using human xenograft or murine syngeneic animal models. These models can be used to advance preclinical drug development efforts. For example, a murine model of subcutaneous colorectal adenocarcinoma (CT26) was used to assess the impact of checkpoint blockade by anti-mPD-1, anti-mPD-L1 or anti-mCTLA-4 on established disease. These regimens were moderately responsive, enabling these data to inform downstream rational combination strategies with these agents.

人和鼠肿瘤模型可用于评估皮下来的那orthotopic，系统性和/或转移性疾病与治疗对疾病进展的影响。